Moreover, our findings suggest that the expression of S100P augments the metastatic potential of HCCs, resulting in high tumor stage, and increases the severity of the disease course, contributing to poor prognosis in HCC patients with high tumor stage or ETR. The gene discussed is S100P; the disease is neoplasm.